New hope for tough blood cancers: drug shows promise after other treatments fail
NCT ID NCT05583552
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests a drug called imetelstat in people with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) whose cancer did not respond to standard treatments. The goal is to see if the drug can improve blood cell counts and control the disease. Participants who respond can keep taking the drug until it stops working. The study involves 46 adults and focuses on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Nantes - Hôtel Dieu
Nantes, France
-
CHU de Toulouse
Toulouse, France
-
Hôpital Archet 1
Nice, France
-
Hôpital Saint-Louis
Paris, France
-
Klinikum rechts der Isar
München, Germany
-
Linear Clinical Research
Nedlands, Australia
-
Marien Hospital Düsseldorf
Düsseldorf, Germany
-
Royal Adelaide Hospital
Adelaide, Australia
-
Royal Brisbane and Women's Hospitals
Brisbane, Australia
-
Universität Jena, Medizinische Fakultät
Jena, Germany
-
Universität Leipzig, Medizinische Fakultät
Leipzig, Germany
Conditions
Explore the condition pages connected to this study.